TransMedics Group (NASDAQ:TMDX) Posts Earnings Results, Misses Expectations By $0.03 EPS

TransMedics Group (NASDAQ:TMDX) issued its quarterly earnings results on Thursday. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.22 by ($0.03), Zacks reports. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group updated its FY 2025 guidance to EPS.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX traded down $1.64 on Thursday, reaching $72.12. The company’s stock had a trading volume of 1,975,687 shares, compared to its average volume of 2,140,839. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a market cap of $2.42 billion, a P/E ratio of 76.72 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The company has a 50-day simple moving average of $67.29 and a 200 day simple moving average of $102.44.

Insider Activity at TransMedics Group

In related news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 7.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on TMDX shares. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Piper Sandler dropped their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Canaccord Genuity Group decreased their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Robert W. Baird decreased their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Finally, TD Cowen dropped their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.